Arnivas 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (2 x 10: ৳ 900.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Opsonin pharma ltd |
| Also available as |
Indications
- Reduce the risk of cardiovascular death
- Reduce hospitalization for heart failure
- Treatment of symptomatic heart failure
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor sacubitril
- Contains angiotensin receptor blocker valsartan
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 receptor via valsartan
Dosage & Administration
- Recommended starting dose for adults: 49/51 mg twice daily
- Pediatric patients aged one year and older: Refer to Table 1 for recommended dose
Interaction
- Should not be used with an ACEi
- Use with an ARB should be avoided
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Lithium may increase risk of lithium toxicity
Contraindications
- Contraindicated in patients with hypersensitivity to any component
- Contraindicated in patients with history of angioedema related to previous ACE inhibitor or ARB therapy
- Contraindicated in concomitant use of ACE inhibitors
- Contraindicated in concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose in severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema and must not be used in patients with known history of angioedema
- Lowers blood pressure and may cause symptomatic hypotension
- Closely monitor serum creatinine
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No starting dose adjustment needed for mild or moderate renal impairment
- Recommended starting dose for moderate hepatic impairment: 24/26 mg twice daily
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available for overdosage
- Hypotension is the most likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children